Test Price
2,800 AED✅ Home Collection Available
DNAAF3 Gene Primary Ciliary Dyskinesia Type 2 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified NGS Processing (Cert: INT/EGQ/2509DA/3139).
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- ✓ Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance by DHA-Licensed Specialists.
- ✓ Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Test Overview & Methodology
The DNAAF3 gene test detects mutations causing primary ciliary dyskinesia type 2 (PCD2) – a rare, autosomal recessive disorder that impairs motile cilia, leading to chronic upper and lower respiratory infections, sinusitis, bronchiectasis, and laterality defects. This NGS-based analysis provides comprehensive coverage of all coding exons, splice sites, and deep intronic regions to ensure high diagnostic yield.
Pre‑Test Information
Provide a detailed clinical history of the patient suspected to have primary ciliary dyskinesia (chronic wet cough, neonatal respiratory distress, recurrent otitis media, situs inversus). A genetic counseling session to draw a pedigree chart of family members potentially affected with PCD is strongly recommended. No fasting or medication changes are required – do not discontinue prescribed medications without consulting your physician. Samples accepted: Whole Blood (EDTA), Extracted DNA, or Dried Blood Spot on FTA card.
| Feature | Our NGS Test (DNAAF3) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | 99.9% analytical sensitivity, full gene coverage | Up to 99%, but limited to known variants |
| Methodology | NGS (Next Generation Sequencing) on Illumina NovaSeq X Plus | Capillary electrophoresis-based Sanger sequencing |
| Turnaround Time | 3 to 4 Weeks | 4 to 6 Weeks |
| Variant Detection | All coding exons, splice sites, deep intronic regions | Targeted mutations only |
Physician Insight & Safety Protocols
“As a DHA-licensed Consultant Medical Genetics, I emphasize that while this NGS test provides high-resolution genetic confirmation of DNAAF3-related primary ciliary dyskinesia, results must always be correlated with clinical presentation, high-speed video microscopy, and nasal nitric oxide levels. A negative report does not exclude other PCD genes, and a multidisciplinary team – including ENT, pulmonology, and genetics – is essential to guide lifelong management.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue prescribed medication without consulting your doctor.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients with severe coagulopathies or active uncontrolled bleeding should inform the phlebotomist; a dried blood spot alternative is suitable.
- ER Red Flags: Seek immediate medical attention if you experience excessive bleeding, fainting, or signs of infection (redness, swelling, fever) at the collection site post‑draw.
- This genetic test is diagnostic but not intended for acute management of respiratory distress – call emergency services if breathing difficulties worsen.
Patient FAQ & Clinical Guidance
1. What is the DNAAF3 gene test and why is it ordered?
This NGS test detects disease‑causing mutations in the DNAAF3 gene to confirm a diagnosis of primary ciliary dyskinesia type 2, a genetic disorder that disrupts motile cilia and causes chronic lung, sinus, and ear infections. Physicians order this test for children and adults with unexplained chronic respiratory problems, situs inversus, or a family history of PCD. A positive result guides targeted therapies, fertility counseling, and specialist follow‑up.
2. How accurate and comprehensive is this NGS test compared to older methods?
With 99.9% analytical sensitivity and full coverage of all coding exons and critical regulatory regions, our NGS platform identifies virtually every clinically relevant variant in DNAAF3, outperforming targeted Sanger sequencing which may miss novel or deep‑intronic mutations. Validation studies against Sanger sequencing and clinical databases confirm that this approach yields less than 1% false‑negative rate, making it the gold standard for molecular diagnosis of primary ciliary dyskinesia type 2.
3. What should I expect after sample collection and how will I receive my results?
After a blood or dried spot collection by our DHA‑licensed phlebotomist, your sample is transported via cold‑chain logistics to our ISO‑certified lab. A comprehensive report will be ready in 3 to 4 weeks, delivered securely online with optional telephonic interpretation by a genetic specialist. You will receive an email notification to download the report from a secure patient portal. Our support team is available on WhatsApp at +971 54 548 8731 for any follow‑up questions or to schedule a tele‑genetics session.
UAE Regulatory & Data Privacy Adherence
This diagnostic service operates in full compliance with UAE federal legislation governing health data and patient privacy. All genetic information is processed under the protections afforded by Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE maintains ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and adheres to DHA regulatory standards for genetic testing and laboratory practice.
Clinical & Logistical Metadata
| Test Name | DNAAF3 Gene Primary Ciliary Dyskinesia Type 2 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or Dried Blood Spot on FTA card |
| Methodology Used | NGS (Next Generation Sequencing) on Illumina NovaSeq X Plus |
| ICD-10-CM Code | Q34.8 |
| LOINC Code | 81247-9 |
| DHA Facility License & Laboratory Address | DHA Facility License: 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians